title: Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.
abstract: Esophageal squamous cell carcinoma (ESCC) is a deadly disease that requires extensive research. In this review, we update recent progress in the research area of targeted therapy for ESCC. SOX2 and its associated proteins (e.g., ΔNP63α), which regulate lineage survival of ESCC cells, are proposed as therapeutic targets. It is believed that targeting the lineage-survival mechanism may be more effective than targeting other mechanisms. With the advent of a new era of personalized targeted therapy, there is a need to move from the tumor-centric model into an organismic model.
authors.affiliation: Department of Cardiothoracic Surgery, 105th Hospital of PLA, Hefei, Anhui Province, China.|Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina.|Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina.
authors.forename: Yongjing
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina.
authors.forename: Zhaohui
authors.initials: Z
authors.lastname: Xiong
authors.affiliation: Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina.
authors.forename: Andrea
authors.initials: A
authors.lastname: Beasley
authors.affiliation: Division of Thoracic Surgery, Duke University Medical Center, Durham, North Carolina.
authors.forename: Thomas
authors.initials: T
authors.lastname: D'Amico
authors.affiliation: Cancer Research Program, Julius L. Chambers Biomedical Biotechnology Research Institute, North Carolina Central University, Durham, North Carolina. lchen@nccu.edu.|Division of Gastroenterology and Hepatology, Department of Medicine, Center for Esophageal Disease and Swallowing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. lchen@nccu.edu.
authors.forename: Xiaoxin Luke
authors.initials: XL
authors.lastname: Chen
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage; D014408:Biomarkers, Tumor / Q000235:genetics*; D002294:Carcinoma, Squamous Cell / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D016503:Drug Delivery Systems / Q000379:methods; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D006801:Humans; D014411:Neoplastic Stem Cells / Q000473:pathology; D057285:Precision Medicine / Q000379:methods*; D055748:SOXB1 Transcription Factors / Q000235:genetics; D014157:Transcription Factors / Q000235:genetics; D059016:Tumor Microenvironment / Q000235:genetics; D025521:Tumor Suppressor Proteins / Q000235:genetics
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C527782:SOX2 protein, human; D055748:SOXB1 Transcription Factors; C115051:TP63 protein, human; D014157:Transcription Factors; D025521:Tumor Suppressor Proteins
keywords: SOX2; esophageal squamous cell carcinoma; lineage survival; targeted therapy